Plasma concentrations of rosuvastatin are increased when co-administered with atazanavir/cobicistat. When co-administration is necessary, do not exceed 10 mg rosuvastatin daily, and clinical monitoring for safety (e.g. myopathy) is recommended. Coadministration of rosuvastatin (10 mg single dose) with atazanavir/cobicistat (300/150 mg once daily) increased rosuvastatin AUC and Cmax by 242% and 958%. There was no change in atazanavir AUC or Cmax, but Cmin increased by 6%.

Coadministration of rosuvastatin (10 mg, single dose) with atazanavir/cobicistat (300/150 mg, once daily) was studied in 16 healthy volunteers. Rosuvastatin Cmax and AUC increased 958% and 242%, respectively. For HMG-CoA reductase inhibitors that are not contraindicated with Evotaz, start with the lowest recommended dose and titrate while monitoring for safety (e.g., myopathy). Rosuvastatin dose should not exceed 10 mg/day.

Coadministration of atazanavir/cobicistat (300/150 mg once daily) and rosuvastatin (10 mg single dose) was studied in 16 HIV-negative subjects. Coadministration increased rosuvastatin AUC and Cmax by 242% and 958%.When atazanavir/cobicistat is coadministered with rosuvastatin, the lowest ROS dose is recommended while monitoring for safety.